Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer

BJU International

Volumn 117, Issue 1, 2016, Pages 102-109

  Cooperberg, Matthew R ^a,b   Hinotsu, Shiro ^c   Namiki, Mikio ^d   Carroll, Peter R ^a   Akaza, Hideyuki ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

androgen deprivation therapy (ADT); CaPSURE; global health; J CaP; prostate neoplasms; risk assessment

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; GONADORELIN AGONIST;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CASTRATION; COMORBIDITY; CONTROLLED STUDY; GENITAL SYSTEM DISEASE ASSESSMENT; HUMAN; JAPAN; JAPAN CANCER OF THE PROSTATE RISK ASSESSMENT SCORE; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; UNITED STATES; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; HUMANS; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; RISK ASSESSMENT; UNITED STATES;

EID: 84951567482     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12937     Document Type: Article

References (38)

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer, 2014: version 1.2014. Available at: http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf. Accessed November 2014
2. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
3. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106-31
4. National comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Asia consensus statement: prostate cancer v 4.2013. Available at: http://www.nccn.org/professionals/physician-gls/PDF/prostate-asia.pdf. Accessed November 2014
5. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005; 12: 46-61
6. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS,. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-24
7. Weight CJ, Klein EA, Jones JS,. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer 2008; 112: 2195-201
8. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-23
9. Krahn M, Bremner KE, Tomlinson G, et al. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use? BJU Int 2011; 108: 1588-96
10. Kuykendal AR, Hendrix LH, Salloum RG, Godley PA, Chen RC,. Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications. Ann Oncol 2013; 24: 1338-43
11. Akaza H, Usami M, Hinotsu S, et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol 2004; 34: 329-36
12. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPSURE), a national disease registry. J Urol 2004; 171: 1393-401
13. Hinotsu S, Akaza H, Usami M, et al. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol 2007; 37: 775-81
14. Cooperberg MR, Hinotsu S, Namiki M, et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009; 27: 4306-13
15. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR,. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 2010; 116: 5226-34
16. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104-11
17. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008; 300: 173-81
18. Saylor PJ, Keating NL, Smith MR,. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med 2009; 24 (Suppl. 2): S389-94
19. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR,. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003; 95: 981-9
20. Bechis SK, Carroll PR, Cooperberg MR,. Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 2011; 29: 235-41
21. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006; 98: 839-45
22. Elliott SP, Jarosek SL, Wilt TJ, Virnig BA,. Reduction in physician reimbursement and use of hormone therapy in prostate cancer. J Natl Cancer Inst 2010; 102: 1826-34
23. Shahinian VB, Kuo Y-F, Gilbert SM,. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 2010; 363: 1822-32
24. Akaza H, Homma Y, Usami M, et al. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int 2006; 98: 573-9
25. Ueno S, Namiki M, Fukagai T, Ehara H, Usami M, Akaza H,. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol 2006; 13: 1494-500
26. Akaza H, Hinotsu S, Usami M, et al. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol 2006; 176: S47-9
27. Akaza H,. Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology 2010; 85: 110-20
28. Yuasa T, Maita S, Tsuchiya N, et al. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 2010; 75: 1131-7
29. Wang W, Yuasa T, Tsuchiya N, et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer 2008; 15: 943-52
30. Maskarinec G, Noh JJ,. The effect of migration on cancer incidence among Japanese in Hawaii. Ethn Dis 2004; 14: 431-9
31. Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M,. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 2006; 97: 1190-3
32. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV,. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009; 302: 866-73
33. Prostate Cancer Trialists Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000; 355: 1491-8
34. Akaza H, Hinotsu S, Usami M, et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 2009; 115: 3437-45
35. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368: 1314-25
36. Cuardo MP, Edwards B, Shin HR, et al. Cancer incidence in five continents, Vol IX. In. IARC Scientific Publications No. 160. Lyon: IARC. Available at: http://www.iarc.fr/en/publications/pdfs-online/epi/sp160/CI5vol9.pdf. Accessed November 2014
37. Robbins AS, Koppie TM, Gomez SL, Parikh-Patel A, Mills PK,. Differences in prognostic factors and survival among white and Asian men with prostate cancer, California, 1995-2004. Cancer 2007; 110: 1255-63
38. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90